New T cell–based immunotherapy shows promise for lethal stem cell transplant complication
More than 60 percent of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was not responding to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called ...
Apr 20, 2015
0
21